The Drive to Discover. The Experience to Deliver.
November 19, 2015
- Patients with intermediate or high-risk myelofibrosis
- Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea
- Worldwide rights to baricitinib licensed to Lilly
- DN = Diabetic nephropathy
- GBM = Glioblastoma multiforme
- Worldwide rights to capmatinib licensed to Novartis